Bio-Manguinhos Report issue

Academic/Hospital Phase 1
Founded: Rio de Janeiro Brazil

Organization Overview

First Clinical Trial
2008
NCT01874457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Immunobiological Technology Institute (Bio-Manguinhos)

Active Ingredients

Drugs in Phase 1 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Drugs in Other Trials (1)

mmr (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2